Welcome & Introduction

Panel Discussion - DIAGNOSTICS IN BREAST CANCER WHERE ARE WE IN 2022

Panel Discussion - Living Longer and Living Well Now a reality in patients with HR+ HER2 aBC

From CLinical Trials to Clinical Practice Navigating managemnet with CDK 4/6 Inhibitors

Clinical utility of Comprehensive Genomic profiling in Breast cancer Management

Management of Her2+ Early Breast Cancer

Role of Her 2 targeted therapy in adjuvant breast cancer

Non Chemotherapy options in advanced Triple positive breast

Immune checkpoint inhibitor use on Breast cancer Key takeaways from SABCS 2021

OLIGOMETASTATIC DISEASE Definitions and Practice Patterns

Closing Remarks